- South Korea
- /
- Biotech
- /
- KOSDAQ:A144510
We Think Green Cross Lab Cell's (KOSDAQ:144510) Robust Earnings Are Conservative
When companies post strong earnings, the stock generally performs well, just like Green Cross Lab Cell Corporation's (KOSDAQ:144510) stock has recently. We did some digging and found some further encouraging factors that investors will like.
View our latest analysis for Green Cross Lab Cell
The Impact Of Unusual Items On Profit
For anyone who wants to understand Green Cross Lab Cell's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit was reduced by ₩1.1b due to unusual items. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. If Green Cross Lab Cell doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Green Cross Lab Cell.
Our Take On Green Cross Lab Cell's Profit Performance
Unusual items (expenses) detracted from Green Cross Lab Cell's earnings over the last year, but we might see an improvement next year. Based on this observation, we consider it likely that Green Cross Lab Cell's statutory profit actually understates its earnings potential! And it's also positive that the company showed enough improvement to book a profit this year, after losing money last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. For example - Green Cross Lab Cell has 1 warning sign we think you should be aware of.
This note has only looked at a single factor that sheds light on the nature of Green Cross Lab Cell's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.
If you’re looking to trade Green Cross Lab Cell, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
About KOSDAQ:A144510
Mediocre balance sheet with low risk.
Market Insights
Weekly Picks

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

Fiducian: Compliance Clouds or Value Opportunity?
Willamette Valley Vineyards (WVVI): Not-So-Great Value
Recently Updated Narratives

Positioned globally, partnered locally

When will fraudsters be investigated in depth. Fraud was ongoing in France too.

Staggered by dilution; positions for growth
Popular Narratives

MicroVision will explode future revenue by 380.37% with a vision towards success

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026
